A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1
Latest Information Update: 30 Apr 2024
At a glance
- Drugs Lumasiran (Primary)
- Indications Primary hyperoxaluria type 1
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 29 Apr 2024 The protocol has been amended to change in change in primary endpoint now the Number of Participants With at Least One Adverse Event up to 54 months.
- 18 Mar 2023 Status changed from active, no longer recruiting to completed.
- 15 Aug 2022 Planned End Date changed from 1 Jun 2023 to 1 Jan 2023.